Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Phase 1

Terminated

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: BCMA-specific CAR-expressing T Lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Gamma-Secretase Inhibitor LY3039478
Other: Laboratory Biomarker Analysis
Other: Pharmacokinetic Study

First Posted Date: 2018-04-18

Last Posted Date: 2024-01-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 19

Registration Number: NCT03502577

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Emphysema or COPD

Interventions: Biological: CD3/CD19 negative hematopoietic stem cells
Drug: Rituximab
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Thiotepa
Drug: G-CSF
Drug: Hydroxyurea

First Posted Date: 2018-04-18

Last Posted Date: 2025-01-09

Lead Sponsor: Paul Szabolcs

Target Recruit Count: 8

Registration Number: NCT03500731

Locations: 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Secondary Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Hematopoietic Cell Transplantation Recipient
Minimal Residual Disease
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Radiation: Total Marrow Irradiation

First Posted Date: 2018-04-11

Last Posted Date: 2024-02-22

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 36

Registration Number: NCT03494569

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3

Active, not recruiting

Conditions: Lymphoma
Myelodysplasia
Plasma Cell Disorder
Acute Myeloid Leukemia
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Myeloproliferative Disorder
Myelofibrosis

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total Body Irradiation
Drug: Tacrolimus
Drug: cellcept
Drug: g-csf
Procedure: Peripheral Blood Transplant

First Posted Date: 2018-03-29

Last Posted Date: 2024-07-23

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 21

Registration Number: NCT03480360

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma

Interventions: Other: TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Nivolumab

First Posted Date: 2018-03-23

Last Posted Date: 2024-02-13

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 18

Registration Number: NCT03475134

Locations: 🇨🇭
CHUV Oncology Department, Lausanne, Vaud, Switzerland

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Phase 1

Active, not recruiting

Conditions: Acute Lymphocytic Leukemia, Pediatric
B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Tocilizumab
Drug: Cytarabine
Drug: Etoposide
Drug: Dexamethasone

First Posted Date: 2018-03-15

Last Posted Date: 2023-02-24

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 18

Registration Number: NCT03467256

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Descartes-08
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-02-28

Last Posted Date: 2024-07-01

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 32

Registration Number: NCT03448978

Locations: 🇺🇸
The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
Virgina Cancer Specialists, Fairfax, Virginia, United States

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2

Active, not recruiting

Conditions: Ovarian Carcinosarcoma
Poorly Differentiated Thyroid Gland Carcinoma
Platinum-Resistant Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Triple Negative Breast Cancer
Bone Sarcoma
Malignancy in Giant Cell Tumor of Bone
Thyroid Gland Anaplastic Carcinoma
Refractory Osteosarcoma
Dedifferentiated Chondrosarcoma

Interventions: Biological: Aldesleukin
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Drug: Cyclophosphamide
Other: Quality-of-Life Assessment
Drug: Fludarabine
Biological: Ipilimumab
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2018-02-28

Last Posted Date: 2024-11-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03449108

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1

Recruiting

Conditions: B-Cell Lymphoma
Acute Lymphocytic Leukemia
B-Cell Leukemia
B-Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, B Cell
Acute Lymphoid Leukemia
B-NHL
Acute Lymphoblastic Leukemia
B-All

Interventions: Biological: CD19/CD22 CAR T-Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-02-28

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT03448393

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CAR-T Cells

First Posted Date: 2018-02-15

Last Posted Date: 2025-01-06

Lead Sponsor: Benjamin Tomlinson

Target Recruit Count: 31

Registration Number: NCT03434769

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy